Skip to search formSkip to main contentSkip to account menu

cariprazine

Known as: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N',N'-dimethylurea hydrochloride 
National Institutes of Health

Related topics

Related topics

6 relations
Antipsychotic AgentsSchizophrenia Spectrum and Other Psychotic Disorderscariprazine 1.5 MG Oral Capsule

Broader (1)

Piperazines

Narrower (2)

RGH-188cariprazine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Cariprazine is an oral antipsychotic approved in the US for the treatment of schizophrenia, acute bipolar mania, and most… 
Review
2019
Review
2019
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder
Bipolar disorder is a chronic, disabling, and costly illness with frequent relapses and recurrences, high rates of co-morbid… 
2018
2018
The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
Cariprazine, a dopamine D3‐preferring D3/D2 receptor partial agonist, is FDA approved for the treatment of schizophrenia and… 
Review
2018
Review
2018
Use of cariprazine in psychiatric disorders: A systematic review.
BACKGROUND Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for… 
2018
2018
Urinary Retention Associated With Cariprazine: A Case Report.
Urinary retention is a well-documented adverse effect of antipsychotic medications and is thought to be mediated by… 
Review
2017
Review
2017
Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis.
2017
2017
P.3.d.008 Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute… 
Review
2016
Review
2016
Cariprazine for Schizophrenia and Bipolar Disorder.
Schizophrenia and bipolar disorder are associated with significant morbidity and mortality. Although atypical antipsychotics… 
2014
2014
Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions
Activation of dopamine D2 receptors (D2R) modulates G protein/cAMP‐dependent signaling and also engages Akt‐GSK‐3 signaling… 
Review
2008
Review
2008
Korean Medication Algorithm for Bipolar Disorder 2006(VI): Comparisons with Other Treatment Guidelines
Korean Medication Algorithm for Bipolar Disorder 2006(VI): Comparisons with Other Treatment Guidelines Bo-Hyun Yoon, MD, Won… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)